Home | Life Sciences Intellectual Property Review
WEB5 days ago — In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results. 24 September 2024 The president of the appeals court reveals his thinking on transparency, bringing more countries on …
Latest News & Features | Life Sciences Intellectual Property Review
WEBDexcom suffers second patent revocation at hands of UPC. The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills. 17 September 2024. Biotechnology.
Americas | Life Sciences Intellectual Property Review
WEB13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
Unified Patent Court | Life Sciences Intellectual Property Review
WEB12 December 2023 Hearing is latest in dispute between the biotech research firms | Multi-jurisdictional case concerns patents relating to the in-situ detection of analytes. 28 November 2023 UPC judge, EPO director and Regeneron counsel shed light on the court’s dynamics at London event | Life sciences sector emerging as a major player in the ...
CRISPR | Life Sciences Intellectual Property Review
WEB9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
Generics | Life Sciences Intellectual Property Review
WEBThe pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP. 28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions ...
2024 forecast: AI, patent eligibility and Fintiv
WEBJan 2, 2024 — NOTE - this can take up to 48hrs to be approved. Two Weeks Free Trial. For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at [email protected]. Americas. Americas. 2024 forecast: AI, patent eligibility and Fintiv.
‘It was like starting all over again’: Tobias Wuttke
WEB4 days ago — For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at [email protected]
EPO’s new examination guidelines: what you need to know
WEBApr 6, 2021 — A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.
UK judge ends J&J unit’s hopes of reviving Stelara patent
WEB4 days ago — UK judge ends J&J unit’s hopes of reviving Stelara patent